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Autosomal recessive Charcot-Marie-Tooth disease (CMT) represents a heterogeneous group of disorders affecting
the peripheral nervous system. The axonal form of the disease is designated as ”CMT type 2” (CMT2), and one
locus (1q21.2-q21.3) has been reported for the autosomal recessive form. Here we report the results of a genomewide
search in an inbred Costa Rican family (CR-1) affected with autosomal recessive CMT2. By analyzing three branches
of the family we detected linkage to the 19q13.3 region, and subsequent homozygosity mapping defined shared
haplotypes between markers D19S902 and D19S907 in a 5.5-cM range. A maximum two-point LOD score of
9.08 was obtained for marker D19S867, at a recombination fraction of .00, which strongly supports linkage to
this locus. The epithelial membrane protein 3 gene, encoding a PMP22 homologous protein and located on 19q13.3,
was ruled out as being responsible for this form of CMT. The age at onset of chronic symmetric sensory-motor
polyneuropathy was 28–42 years (mean 33.8 years); the electrophysiological data clearly reflect an axonal degen-
erative process. The phenotype and locus are different from those of demyelinating CMT4F, recently mapped to
19q13.1-13.3; hence, the disease affecting the Costa Rican family constitutes an axonal, autosomal recessive CMT
subtype (ARCMT2B).
Charcot-Marie-Tooth disease (CMT [MIM 118200]) is
part of a complex group of clinically and genetically
heterogeneous hereditary motor and sensory neuropa-
thies (HMSN) (Dyck et al. 1993; Lupski 1999). On the
basis of electrophysiological criteria, CMT is divided
into CMT type 1 (CMT1, the demyelinating form), char-
acterized by a motor median nerve conduction velocity
(NCV) !38 m/s, and CMT type 2 (CMT2, the axonal
form), with a normal or slightly reduced NCV. At least
nine different genes and loci, as well as an increased
phenotypic variability, have been associated with an in-
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herited motor and/or sensory axonal phenotype (Vance
2000). Common types of CMT2 with similar pheno-
types have been mapped to chromosome 1p36 (CMT2A
[MIM 118210]) and to chromosome 7p15 (CMT2D
[MIM 601472]) (Ben Othmane et al. 1993b; Ionasescu
et al. 1996). Recently, mutations in the neurofilament-
light gene (NEFL [MIM 162280]), located on chro-
mosome 8p21, were identified for the CMT2E form
(Mersiyanova et al. 2000). For patients with only slightly
decreased NCV, mutations in the genes encoding con-
nexin 32 (Cx32 [MIM 304040]) and myelin protein zero
(MPZ [MIM 159440]) have been reported as well (Tim-
merman et al. 1996; Birouk et al. 1998; Marrosu et al.
1998; Senderek et al. 2000). For the Thr124Met MPZ
mutation, a distinct CMT2 phenotype with pupillary
anomalies and deafness has been reported in several
studies (Chapon et al. 1999; De Jonghe et al. 1999).
Both the autosomal recessive demyelinating form
(CMT4) and the autosomal recessive axonal form
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(ARCMT2) are less frequently observed. Two recently
discovered disease-causing genes and several loci have
been reported for autosomal recessive demyelinating
CMT4: the myotubularin-related protein-2 (MTMR2
[MIM 603557]) gene has been located on chromosome
11q22 (Bolino et al. 2000) and, on chromosome
8q24, the N-myc downstream regulated gene 1 (NDRG1
[MIM 605262]) was identified as being responsible for
HMSN-Lom (Kalaydjieva et al. 2000 [MIM 601455]);
further loci were described on chromosome 8q13-21.1
(Ben Othmane et al. 1993a); 11p15 (Ben Othmane et
al. 1999); 5q23-33 (LeGuern et al. 1996); 10q21-22,
which has mutations in the early growth response gene
2 (EGR2 [MIM 129010]) (Warner et al. 1998); and
10q23 (Rogers et al. 2000). For the autosomal recessive
inherited axonal ARCMT2, one locus was mapped on
1q21.2-q21.3; the MPZ gene was ruled out as a can-
didate (Bouhouche et al. 1999).
Here we report linkage to chromosome 19q13.3 of
an autosomal recessive CMT disease with the axonal
phenotype (ARCMT2) that affects three branches of a
large consanguineous family (CR-1) in Costa Rica. The
family, which is of predominantly Spanish ancestry, orig-
inates from a single town in the province of Alajuela,
Republic of Costa Rica. Among the 31 family members
analyzed, 18 were classified as affected with the disease
(fig. 1). Informed consent was obtained from each par-
ticipant. For one patient (B-5.3) no data were available.
At the date of examination the ages of the patients were
32–49 years (mean 39.3 years), with a disease duration
of 2–15 years (mean 5.5 years). Age at onset of disease
was 28–42 years (mean 33.8 years).
Clinically, all patients presented with symmetrical
weakness of the plantar extensor and flexor muscles of
the ankles. The clinical and electrophysiological features
of 6 of the 17 patients could be analyzed in more detail.
Four out of the six patients presented with distal weak-
ness in the upper extremities, ranging from slight pare-
sis to severe involvement of the small hand muscles. Dis-
tal atrophy of the plantar muscles was present in five
patients, three of whom also showed atrophy of the
small hand muscles. Ankle jerks were weak in one pa-
tient and absent in all others; three patients even pre-
sented with areflexia. All patients showed sensory def-
icit in a symmetrical “stocking-glove” pattern. Five
patients presented with distal hypaesthesia and hypal-
gesia and a decreased sense of vibration and position in
the lower extremities, and in three patients the upper
extremities were also affected. In one patient only, the
senses of vibration and position were decreased in the
upper and lower extremities. In all patients, motor-nerve
conduction velocity (MCV) of the median and the ulnar
nerves was normal or slightly reduced, with ranges of
28.8–54.5 m/s (mean 43.9 m/s) for the median nerve
and 40.0–64.7 m/s (mean 53.2 m/s) for the ulnar nerve.
In one patient, MCV of the median and ulnar nerves
was not detectable. MCV of the tibial nerve could be
detected in only three of six patients and was 35–40.7
m/s (mean 37.9 m/s). MCV of the peroneal nerve could
be detected in only two patients, with values of 30.6 m/
s and 32.7 m/s. In one patient, sensory nerve action
potentials (SNAPs) of the median and ulnar nerves could
be detected. In this patient, sensory nerve conduction
velocity of the median (42.4 m/s) and ulnar (40 m/s)
nerves was slightly reduced. SNAPs of sural nerves were
not detectable in any patient. Neurographically, ampli-
tudes were decreased in affected nerves, and motor and
sensory nerve potentials did not show temporal disper-
sion. Electromyography of the right anterior tibial mus-
cle showed an increased number of polyphasic motor-
unit potentials in all patients and increased amplitudes
of the motor-unit potentials (4.7–6.0 mV) in four of six
patients. These electrophysiological data clearly reflect
an axonal degenerative process. A sural nerve biopsy
was not performed.
Initially, SSCP analysis of the MPZ, PMP22, and
EGR2 genes failed to reveal a mutation, and the vari-
ous loci known to be linked to the different hereditary
motor and sensory neuropathies could also be excluded
after linkage analysis with microsatellites from the re-
spective regions (LOD score !2, data not shown). Fi-
nally, a genomewide screening was performed with fluo-
rescent microsatellite markers at a resolution of 10 cM.
The coordinates of the markers were taken from the
Ge´ne´thon human linkage map. The order was confirmed
through use of the haplotypes generated in this study
and the program CRI-MAP, version 2.41, with the
“ALL” option chosen (Documentation for CRI-MAP
Version 2.4 Web site; also see Green 1992). The PCR
products were pooled, loaded onto 5% polyacrylamide
gels, and separated on an ABI 377 DNA sequencer (PE
Biosystems); the data were analyzed with GENESCAN
(version 2.1) and GENOTYPER (version 1.1; PE Biosys-
tems) software.
On the basis of the segregation pattern observed in
this family, we performed linkage calculations under as-
sumptions of autosomal recessive inheritance, a disease-
gene frequency of .0001, and uniform marker-allele fre-
quencies. Given the late age at onset of the disease,
individual B-4.4 (41 years old) was analyzed under the
assumption of 90% penetrance. All other healthy mem-
bers of the family were analyzed under the assumption
of 99% penetrance, because their ages were 150 years.
The family was divided into three branches in order to
make the linkage analysis possible. All three branches
were analyzed, with PEDCHECK software, for Men-
delian incompatibilities of the genotypes (O’Connel and
Weeks 1998), and two-point LOD scores were calculated
with the LINKAGE software package, version 5.2 (La-
throp et al. 1985; Ott 1991; Cottingham et al. 1993).
Figure 1 Pedigree and haplotype analysis of markers from chromosome 19q13 in members of family CR-1, from Costa Rica, with
ARCMT2B. Haplotypes segregating with the disease are given in black. Although the exact genealogical connection is not shown, because of
the complexity of the family structure, branches A, B, and C have common ancestors. Healthy members of the families, not used for linkage
analysis, are summarized to the right of the nuclear families, showing the number of individuals in each case.
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Table 1
Two-Point LOD Scores for the Autosomal Recessive CMT Locus in the Costa Rican ARCMT2 Family with
Markers from Chromosome 19q13
MARKER
DISTANCE
(CM)a
LOD SCORE AT v pb
Zmax vmax.0 .001 .01 .05 .1 .2 .3 .4
D19S412 69.9 1.84 3.73 5.49 6.06 5.60 4.07 2.35 .83 6.07 .042
D19S606 76.2 3.70 4.85 5.66 5.64 5.04 3.51 1.95 .65 5.79 .024
D19S902 76.2 4.69 5.63 6.42 6.37 5.72 4.09 2.36 .84 6.54 .023
D19S879 78.9 7.61 7.60 7.44 6.72 5.81 3.96 2.18 .72 7.61 .000
D19S604 79.0 7.17 7.15 7.00 6.33 5.48 3.76 2.12 .78 7.17 .000
D19S867 81.2 9.08 9.07 8.88 8.09 7.08 5.02 2.97 1.16 9.08 .000
D19S907 81.7 2.65 5.93 6.75 6.64 5.91 4.13 2.31 .76 6.85 .022
a According to the Ge´ne´thon linkage map.
b Cumulative LOD scores were obtained from the analysis of the three family branches.
Figure 2 Critical region of ARCMT2B on chromosome
19q13.3. Key recombinations are shown in individuals C-3.1 and A-
5.1, defining the ARCMT2B interval identified in the Costa Rican
family. The gene that causes this form of CMT is located in a 5.5-cM
region between D19S902 and D19S907. The linkage map of markers
from chromosome 19 and genetic distances (in centimorgans) are as-
signed based on information from the Ge´ne´thon human linkage map.
Blackened regions in chromosomal representations indicate haplotypes
related to the disease, and unblackened regions indicate haplotypes
not related to the disease.
The LOD scores for the three branches were summed.
Finally, linkage to markers on chromosome 19q13.3was
identified. Maximum two-point LOD scores (Zmax) were
obtained for marker D19S867 ( ; table 1).Z p 9.08max
This marker, as well as D19S879 and D19S604, segre-
gated fully with the disease in the family. Key recombina-
tion events were observed between markers D19S902
and D19S879 in patient A-5.1 , and between D19S907
and D19S867 in patient C-3.1 (fig. 1). These recombi-
nation events locate the interval of interest between
D19S902 and D19S907, with a length of 5.5 cM (fig.
2). All patients are homozygous for the same haplotype
in this critical region.
The interval defined in this Costa Rican family with
ARCMT2 is different from the one recently described in
a Lebanese family with CMT4F (Delague et al. 2000).
The interval in the Lebanese family is located between
D19S220 and D19S412, at least 6.3 cM proximal to the
one reported here. Ancestral recombination events ob-
served in the haplotype analysis of several individuals
also support the exclusion of that interval (fig. 1). Two
genes associated with autosomal recessive CMT are in the
immediate neighborhood, and this genetic heterogeneity
is in accordance with the different phenotypes—myeli-
nopathy versus axonal type—in both families. Consid-
ering that this is the second autosomal recessive CMT
type 2 locus, we propose the terms “ARCMT2A” for the
locus on chromosome 1q21.2-21.3, described by Bou-
houche et al. (1999), and “ARCMT2B” for the locus
described in the present study.
The epithelial membrane protein-3 (EMP3, MIM
602335) has been mapped to chromosome 19q13.3
(Liehr et al. 1999). EMP3 is a member of the four-trans-
membrane-domain gene family that also includes the
peripheral myelin protein 22 (PMP22 [MIM 601097];
Taylor and Suter 1996). Given its position and the fact
that PMP22 is involved in peripheral polyneuropathies
(Lupski 1999; Nelis et al. 1999a, 1999b), EMP3 was
considered as a candidate gene for the ARCMT2 disease
reported in the present study. The function of this protein
is unknown, but, on the basis of the available data for
PMP22, it could be involved in cell proliferation and
cell-cell interactions (Taylor and Suter 1996). The com-
plete sequence of the EMP3 cDNA (GenBank accession
number X94771) was compared with that of the ge-
nomic clone AC020955 (GenBank), using BLAST to de-
termine the intron-exon structure. The four coding ex-
ons of EMP3 were PCR-amplified with the following
intronic primers: exon 1, forward (5′-CAACCTCTTGA-
GACTCCGTC-3′) and reverse (5′-GGACAGAGTGAG-
ACCCTTGT-3′); exon 2, forward (5′-CCTCTCCTTTC-
CTAACCCTG-3′) and reverse (5′-GGTTCCCAATTC-
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TCAGTCCC-3′); exon 3, forward (5′-AACTCTGGAC-
CCACGGTGAT-3′) and reverse (5′-CCCACTCCCTTC-
TGCTCAAT-3′); and exon 4, forward (5′-GGGAAATG-
TAGTCTTGAGGG-3′) and reverse (5′-GAAGGAAG-
ATCAAGGCAGAG-3′). PCR products from two obli-
gate carriers (B-4.5 and B-4.6), a patient (B-5.2), and a
healthy control were tested through use of a denaturing
HPLC system (WAVE, Transgenomics) at various sep-
aration temperatures (Kuklin et al. 1997–98). In addi-
tion, amplified products from a healthy control, an ob-
ligate carrier (B-4.5), and a patient (B-5.2) were se-
quenced on both strands with a BigDye Terminator Cy-
cle Sequencing Kit on an ABI 377 DNA sequencer (PE
Biosystems), according to standard protocols.
None of the analyzed individuals presented hetero-
duplexes in the denaturing high-performance liquid
chromatography system, and the subsequent sequence
analysis of the four coding exons revealed no variation
from the cDNA sequence reported elsewhere (Taylor and
Suter 1996). Similarly, the adjacent intronic sequences
were identical between the healthy control and patient
B-5.2, thus excluding the possibility of a splice-site mu-
tation. Therefore, EMP3 was ruled out as a candidate
gene for ARCMT2B. No other obvious candidate genes
for a motor and sensory neuropathy with axonal im-
plications were identified. Further refinement of the in-
terval defined in the present study may reduce the num-
ber of positional candidate genes that need to be
analyzed for the presence of mutations in order to iden-
tify the causative gene.
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